Australian-based Chrysos Corporation says it is tracking at the upper end of its fiscal 2026 earnings and revenue guidance after hitting one million samples processed in a month with its PhotonAssay fleet for the first time in March and repeating the dose in April.
The company said the sample milestone underscored rising global PhotonAssay use and productivity.
Its alternative method of analysing gold and other mineral samples, replacing conventional fire assaying, is being used by a number of large miners, contractors and mineral testing groups.
Chrysos says it is trading in line with its FY26 targets: A$80-90 million revenue and $20-27 million EBITDA. It said sample volumes underpinned higher utilisation and additional assay charges, or AAC, “a key revenue and profitability driver”.
So far in 2026 the company has signed 19 new PhotonAssay lease agreements, “reflecting Chrysos’ broadening international relationship with both miners and laboratories”.
“A further three units have completed factory acceptance testing and eight PhotonAssay units are now either being shipped to, or are stored near, their deployment locations as we look to accelerate deployments into FY27,” the company said.
Chrysos said its previously announced refinancing to a total level of $200 million remained on track for completion by June 30 this year.
The company’s share price has nearly doubled in the past 12 months, giving it a current market capitalisation of about $883 million. It did spike above $1 billion earlier this year.
